Johnson & Johnson (NYSE:JNJ) is Strategic Advisors LLC’s 6th Largest Position

Posted by Defense World Staff on Jul 25th, 2023

Strategic Advisors LLC boosted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 6.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 86,871 shares of the company’s stock after acquiring an additional 5,400 shares during the quarter. Johnson & Johnson accounts for about 2.7% of Strategic Advisors LLC’s holdings, making the stock its 6th biggest holding. Strategic Advisors LLC’s holdings in Johnson & Johnson were worth $13,465,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. GW&K Investment Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $35,000. Dark Forest Capital Management LP grew its holdings in shares of Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares during the last quarter. Retirement Financial Solutions LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $40,000. Ruedi Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $42,000. Finally, Kepos Capital LP purchased a new position in Johnson & Johnson during the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 67.57% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $171.10 on Tuesday. The firm has a 50 day moving average of $160.60 and a 200-day moving average of $161.20. The company has a market cap of $444.64 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 2.88 and a beta of 0.55. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The business had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same period in the prior year, the business earned $2.59 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.78%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Insider Activity

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday. Citigroup assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price for the company. Raymond James upped their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a research note on Monday. Credit Suisse Group boosted their target price on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday. Finally, StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $171.60.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.